News

At the San Antonio Breast Cancer Symposium in December, Roche presented the data from its phase 3 Katherine trial, a head-to-head test of Kadcyla versus Herceptin in 1,500 patients.
Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease progressing.
Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new survival data to be presented at the upcoming ASCO congress looks set ...
FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation F. Hoffmann-La Roche Ltd Wed, May 29, 2024, 1:00 AM 11 ...
Roche Holding said the U.S. Food and Drug Administration granted priority review to the company's new drug application for inavolisib as a treatment for a type of advanced breast cancer. The Swiss ...
AbbVie and Genmab have glided into Roche’s slipstream in the race to bring a CD3xCD20 bispecific to market, securing FDA priority review and a May decision date—and triggering an $80 million ...
Roche (OTCQX:RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of a certain type of breast cancer with a PIK3CA mutation. The agency ...
Itovebi won US Food and Drug Administration (FDA) approval in this breast cancer indication based on INAVO120’s data late last year, although full analysis of the OS has only been completed by ...
Roche RHHBY announced that the FDA has approved pipeline candidate, inavolisib, for the treatment of breast cancer, under the brand name Itovebi.. The drug is approved in combination with Pfizer ...